Condition: COPD (Chronic Obstructive Pulmonary Disease) · Sponsor: AstraZeneca
Observational, prospective, multicenter cohort study with consecutive inclusion of COPD patients. Eligible patients will be those with severe and very severe COPD according to the GOLD 2024 (Global Initiative for Chronic Obstructive Lung Disease) guidelines being followed at participating hospitals. The severity of COPD is related to the exacerbation rate, which in turn is related to the progression of the disease and the occurrence of complications and death. There is no national data on this subgroup.
This description comes directly from the study's public registry record.
AstraZeneca Clinical Study Information Center · 1-877-240-9479 · information.center@astrazeneca.com
Always discuss trial participation with your own doctor first.
| Research Site | Aparecida de Goiânia, Brazil | Recruiting |
| Research Site | Bahia, Brazil | Recruiting |
| Research Site | Belém, Brazil | Recruiting |
| Research Site | Brasília, Brazil | Recruiting |
| Research Site | Campo Grande, Brazil | Recruiting |
| Research Site | Florianópolis, Brazil | Not Yet Recruiting |
| Research Site | Goiânia, Brazil | Recruiting |
| Research Site | Santo André, Brazil | Recruiting |
| Research Site | São Paulo, Brazil | Recruiting |
| Research Site | Uberlândia, Brazil | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06780046